USE OF INDICATORS OF CATALASE ACTIVITY FOR DIFFERENTIAL DIAGNOSTICS OF MALIGNANT AND BENIGN TUMORS OF BRAIN

The article presents the results of determining the activity of one of the components of antioxidant protection – blood catalase and brain tumor cells. The subject of the study was blood and postoperative material of tumor neoplasms of the brain of 12 patients with malignant brain tumors (glioma, glioblastoma, astrocytoma), 7 patients with benign brain tumors (meningioma, subependymoma) prior to treatment. As a control the brain tissue of people used who died as a result of trauma, and blood from 10 healthy people. Also as a model of hypoxia, brain tissue was studied from 7 persons who died from cardiovascular insufficiency.The study of catalase activity included the quantitative detection by Beer and Sizer (1952), based on the decrease in optical density in the light absorption region of hydrogen peroxide at 240 nm. Statistical processing of data was carried out using Biostat 4.3. Catalase activity in tumor tissues was significantly higher in malignant and benign neoplasms of the brain compared to that of the control group. An interesting result of the study was the fact that the activity of catalase in the brain during hypoxia has also significantly increased. The activity of catalase in erythrocytes was significantly lower for brain tumors compared to practically healthy people. With malignant neoplasms of the brain, the catalase activity decreased more significantly – by more than 3 times, than in benign tumors – by 1,4 times. Thus, the determination of the activity of catalase of blood can be used for the purpose of early differential diagnosis in benign and malignant neoplasms of the brain, which will significantly increase the effectiveness of treatment and lead to reduction in mortality from malignant brain tumors